EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 721 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends Extension of Indications for Niraparib September 29, 2020 Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the... September 10, 2021 Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... July 5, 2023 Withdrawal of the Application to Change the EMA Marketing Authorisation for... December 2, 2022 Load more HOT NEWS Cancer Research UK thanks Tania Bryer for a decade of fundraising... Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event... Frederick National Laboratory for Cancer Research: A Unique Resource for the...
